FDA Approves CDK4/6 Inhibitor, Kisqali, to Treat Type of Metastatic Breast Cancer

FDA Approves CDK4/6 Inhibitor, Kisqali, to Treat Type of Metastatic Breast Cancer
The U.S. Food and Drug Administration has approved Kisqali (ribociclib), in combination with an aromatase inhibitor as first-line treatment for post-menopausal and hormone-positive, HER2-negative metastatic breast cancer patients. The approval was granted to Novartis under the FDA’s breakthrough therapy designation and priority review programs. It was based on data from a Phase 3 trial assessing

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *